Advanced search
Publication Cover
Expert Review of Anticancer Therapy Volume 23, 2023 - Issue 10: Triple negative breast cancer
Submit an article Journal homepage
631
Views
0
CrossRef citations to date
0
Altmetric
Editorial

How can we refine the prognostic stratification of triple-negative breast cancer?

Federica Migliettaa Oncology Unit 2, Istituto Oncologico Veneto, IOV-IRCCS, (Via Gattamelata 64, Padova, Italy;b Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, ItalyView further author information
&
Maria Vittoria Diecia Oncology Unit 2, Istituto Oncologico Veneto, IOV-IRCCS, (Via Gattamelata 64, Padova, Italy;b Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, ItalyCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-3967-9861View further author information
ORCID Icon
Pages 1045-1047 | Received 24 Jul 2023, Accepted 10 Aug 2023, Published online: 17 Aug 2023

References

  • Bianchini G, Angelis CD, Licata L, et al. Treatment landscape of triple-negative breast cancer — expanded options, evolving needs. Nat Rev Clin Oncol. 2022;19(2):91–113. doi: 10.1038/s41571-021-00565-2
  • Salgado R, Denkert C, Demaria S, et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an international TILs Working group 2014. Ann Oncol. 2015;26(2):259–271. doi: 10.1093/annonc/mdu450
  • Cardoso F, Kyriakides S, Ohno S, et al. Early breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30(8):1194–1220. doi: 10.1093/annonc/mdz173
  • Burstein HJ, Curigliano G, Thürlimann B, et al. Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021. Ann Oncol. 2021;32(10):1216–1235. doi: 10.1016/j.annonc.2021.06.023
  • Loi S, Drubay D, Adams S, et al. Tumor-infiltrating lymphocytes and prognosis: a pooled individual patient analysis of early-stage triple-negative breast cancers. J Clin Oncol. 2019;37(7):559–569. doi: 10.1200/JCO.18.01010
  • Loi S, Salgado R, Adams S, et al. Tumor infiltrating lymphocyte stratification of prognostic staging of early-stage triple negative breast cancer. NPJ Breast Cancer. 2022;8(1):3. doi: 10.1038/s41523-021-00362-1
  • Prowell TM, Pazdur R. Pathological complete response and accelerated drug approval in early breast cancer. N Engl J Med. 2012;366(26):2438–2441. doi: 10.1056/NEJMp1205737
  • Prowell TM, Beaver JA, Pazdur R. Residual disease after neoadjuvant therapy - developing drugs for high-risk early breast cancer. N Engl J Med. 2019;380:612–615. doi: 10.1056/NEJMp1900079
  • Yau C, Osdoit M, van der NM, et al. Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients. Lancet Oncol. 2022;23(1):149–160. doi: 10.1016/S1470-2045(21)00589-1
  • Dieci MV, Tsvetkova V, Griguolo G, et al. Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: analysis of 244 stage I–III patients treated with standard therapy. Eur J Cancer. 2020;136:7–15. doi: 10.1016/j.ejca.2020.05.014
  • Gluz O, Nitz U, Kolberg-Liedtke C, et al. De-escalated neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC): impact of molecular markers and final survival analysis of the WSG-ADAPT-TN trial. Clin Cancer Res. 2022;28(22):4995–5003. doi: 10.1158/1078-0432.CCR-22-0482
  • Dieci MV, Criscitiello C, Goubar A, et al. Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study. Ann Oncol. 2014;25(3):611–618. doi: 10.1093/annonc/mdt556
  • Luen SJ, Salgado R, Dieci MV, et al. Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple-negative breast cancer patients after neoadjuvant chemotherapy. Ann Oncol. 2019;30(2):236–242. doi: 10.1093/annonc/mdy547
  • Dieci MV, Carbognin L, Miglietta F, et al. Incorporating weekly carboplatin in anthracycline and paclitaxel-containing neoadjuvant chemotherapy for triple-negative breast cancer: propensity-score matching analysis and TIL evaluation. Br J Cancer. 2023;128(2):266–274. doi: 10.1038/s41416-022-02050-8
  • Magbanua MJM, Swigart LB, Ahmed Z, et al. Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy. Cancer Cell. 2023;41(6):1091–1102.e4. doi: 10.1016/j.ccell.2023.04.008
  • Simon R. Clinical trial designs for evaluating the medical utility of prognostic and predictive biomarkers in oncology. Per Med. 2010;7(1):33–47. doi: 10.2217/pme.09.49
  • Guo J, Hu J, Zheng Y, et al. Artificial intelligence: opportunities and challenges in the clinical applications of triple-negative breast cancer. Br J Cancer. 2023;128(12):2141–2149. doi: 10.1038/s41416-023-02215-z

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.